Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM7V2LG)

• Drug Name: Chrysin Drug Info
• Synonyms: chrysin; 480-40-0; 5,7-Dihydroxyflavone; Chrysine; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Crysin; 5,7-dihydroxy-2-phenylchromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; UNII-3CN01F5ZJ5; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; EINECS 207-549-7; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL117; NSC 407436; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; CHEBI:75095; RTIXKCRFFJGDFG-UHFFFAOYSA-N; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; MFCD00006834; Chrysin, 99+%; CAS-480-40-0
• Cross-matching ID:
  PubChem CID: 5281607
  ChEBI ID: CHEMBL117
  CAS Number: CAS 480-40-0
  TTD Drug ID: D01UYI
  VARIDT Drug ID: DR01258
  INTEDE Drug ID: DR1939

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
DNA replication	2.34	0.00e+0	34/36 (94.44%)	PCNA;POLE2;MCM6;...
Drug metabolism	2.17	0.00e+0	78/151 (51.66%)	GSTA1;GSTP1;UPP1;...
Pyrimidine metabolism	1.87	7.41e-3	40/56 (71.43%)	TYMS;UPP1;DUT;...
Glycine, serine and threonine metabolism	1.80	1.85e-2	31/40 (77.5%)	CBS;PSPH;GCAT;...
One carbon pool by folate	1.73	3.85e-2	15/20 (75%)	TYMS;SHMT2;SHMT1;...
Th17 cell differentiation	-1.75	3.97e-2	95/107 (88.79%)	RXRA;SMAD3;IL6ST;...
Th1 and Th2 cell differentiation	-1.75	4.47e-2	80/92 (86.96%)	IL5;IL13;IKBKG;...
Cytokine-cytokine receptor interaction	-1.79	3.29e-2	246/295 (83.39%)	BMP6;CXCL13;TNFRSF9;...
Neutrophil extracellular trap formation	-1.81	2.77e-2	101/189 (53.44%)	RAF1;CLEC7A;C5AR1;...
PPAR signaling pathway	-1.82	3.32e-2	66/74 (89.19%)	RXRB;HMGCS1;PCK1;...
ECM-receptor interaction	-1.84	2.87e-2	80/88 (90.91%)	ITGA10;GP1BB;FN1;...
Viral protein interaction with cytokine and cytokine re...	-1.86	3.41e-2	84/100 (84%)	TNFRSF10C;CCR3;CXCL13;...
Salivary secretion	-1.90	3.19e-2	76/93 (81.72%)	RYR3;GUCY1B1;ADCY2;...
Adipocytokine signaling pathway	-1.95	2.56e-2	64/69 (92.75%)	PTPN11;LEP;RXRA;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H	Show ▼